# LFSC (F/m Emerald Life Sciences Innovation ETF)

F/m · Thematic ETFs · data as of Sep 18, 2026

LFSC holds 39 stocks, and 100% of its weight is outside the S&P 500.

## Key facts

- LFSC, already in the S&P 500: 0.0%, as of Sep 18, 2026.
- LFSC, active share vs the S&P 500: 100.0%, as of Sep 18, 2026.
- LFSC, top ten holdings: 54.7%, as of Sep 18, 2026.
- LFSC, total return, 1 year: +53.0%, as of Sep 18, 2026.
- LFSC, net assets: $105m (SEC filing, whole fund, as filed for May 31, 2026).
- LFSC, expense ratio: 0.54% (485BPOS XBRL, Dec 30, 2025).

## LFSC over each window to Sep 18, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +8.7% | +2.3% | +6.5 pts | +11.2 pts |
| 6 months | +36.0% | +18.0% | +17.9 pts | +11.7 pts |
| 1 year | +53.0% | +16.6% | +36.5 pts | +31.3 pts |
| Since launch | +81.3% | +37.0% | +44.3 pts | +30.9 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Broad innovation and megatrends | ETFIQ, editorial |
| Launched | Oct 31, 2024 | ETFIQ |
| Already in the S&P 500, by weight | 0.0% | ETFIQ |
| Active share vs the S&P 500 | 100.0% | ETFIQ |
| Already in the Nasdaq-100, by weight | 0.6% | ETFIQ |
| Active share vs the Nasdaq-100 | 99.9% | ETFIQ |
| Top ten holdings weight | 54.7% | ETFIQ |
| Holdings | 39 | ETFIQ |
| Holdings as of | May 31, 2026 | SEC N-PORT |
| Top holdings | Travere Therapeutics Inc 7.7%, Cogent Biosciences Inc 7.5%, LivaNova PLC 7.1%, Spyre Therapeutics Inc 6.4%, Guardant Health Inc 5.5%, Mirum Pharmaceuticals Inc 4.9%, Corcept Therapeutics Inc 4.8%, United Therapeutics Corp 4.2%, VeraDermics Inc 3.4%, Savara Inc 3.2% | ETFIQ |
| Net assets | $105m | SEC filing, whole fund, as filed for May 31, 2026 |
| Below its all-time high | −6.8% | ETFIQ |
| Expense ratio | 0.54% | 485BPOS XBRL, Dec 30, 2025 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.54% | ETFIQ |
| Closest funds by holdings overlap | HELX 16%, HLTH 13%, FMED 11%, EKG 11%, FBT 10% | ETFIQ |

## Questions

### How much of LFSC is in S&P 500 companies?

By its holdings filed for May 31, 2026, 0% of LFSC by weight is stocks the S&P 500 already holds. Its active share against the index is 100%, so that share is the part doing something different.

### What does LFSC hold?

39 positions as filed for May 31, 2026, with the top ten at 55% of the fund. The largest are Travere Therapeutics Inc at 7.7%, Cogent Biosciences Inc at 7.5%, LivaNova PLC at 7.1%.

### Has LFSC beaten the S&P 500?

Over the year to Sep 18, 2026 LFSC returned +53.0% with distributions reinvested, against +16.6% for the S&P 500, so it finished ahead of the index by 36.5 points.

### What does LFSC cost?

The prospectus expense ratio is 0.54% a year. Because 100% of the fund differs from the S&P 500, the fee on that differing part works out at 0.54%.


## Cite this page

ETFIQ, LFSC, data as of Sep 18, 2026. https://etfiq.com/funds/lfsc
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/lfsc  ·  JSON: https://etfiq.com/funds/lfsc.json